107 related articles for article (PubMed ID: 1551255)
1. Long-term effects on lymphocytotoxic antibodies and immune reactivity in hemodialysis patients treated with recombinant human erythropoietin.
Bárány P; Fehrman I; Godoy C
Clin Nephrol; 1992 Feb; 37(2):90-6. PubMed ID: 1551255
[TBL] [Abstract][Full Text] [Related]
2. Effect of human recombinant erythropoietin therapy on panel reactive antibodies in chronic dialysis patients.
Friedlaender MM; Azem O; Rubinger D; Brautbar C
Isr J Med Sci; 1996 Sep; 32(9):730-6. PubMed ID: 8865827
[TBL] [Abstract][Full Text] [Related]
3. [Post-transfusional anti-HLA hyperimmunization: importance of erythropoietin].
Mourad G; Chong G; Cristol JP; Lorho R; Ramounau-Pigot A; Seignalet J
Nephrologie; 1993; 14(2):91-4. PubMed ID: 8327032
[TBL] [Abstract][Full Text] [Related]
4. Renormalization of high cardiac output and of left ventricular size following long-term recombinant human erythropoietin treatment of anemic dialyzed uremic patients.
Cannella G; La Canna G; Sandrini M; Gaggiotti M; Nordio G; Movilli E; Maiorca R
Clin Nephrol; 1990 Dec; 34(6):272-8. PubMed ID: 2073771
[TBL] [Abstract][Full Text] [Related]
5. [The use of recombinant erythropoietin with patients on programmed hemodialysis].
Rozental' RL; Zezina LIu; Spudass AV
Ter Arkh; 1991; 63(12):110-3. PubMed ID: 1803587
[TBL] [Abstract][Full Text] [Related]
6. Evidence that treatment of ESRD patients with recombinant human erythropoietin induces immunosuppression without affecting the distribution of peripheral blood mononuclear cell subpopulations.
Steffensen G; Aunsholt NA; Povlsen JV
Clin Nephrol; 1996 Feb; 45(2):98-103. PubMed ID: 8846537
[TBL] [Abstract][Full Text] [Related]
7. Human recombinant erythropoietin treatment in transfusion dependent anemic patients on maintenance hemodialysis.
Zehnder C; Blumberg A
Clin Nephrol; 1989 Feb; 31(2):55-9. PubMed ID: 2920469
[TBL] [Abstract][Full Text] [Related]
8. Lymphocyte 5'-nucleotidase and aminopeptidase N activity in patients on maintenance hemodialysis treated with human recombinant erythropoietin and 1-alpha-D3.
Stefanovic V; Mitić-Zlatkovic M; Radivojevic J; Vlahovic P
Ren Fail; 2005; 27(3):283-8. PubMed ID: 15957544
[TBL] [Abstract][Full Text] [Related]
9. Nutritional assessment in anemic hemodialysis patients treated with recombinant human erythropoietin.
Bárány P; Pettersson E; Ahlberg M; Hultman E; Bergström J
Clin Nephrol; 1991 Jun; 35(6):270-9. PubMed ID: 1873941
[TBL] [Abstract][Full Text] [Related]
10. Recombinant human erythropoietin (rhEPO) treatment potentiates growth hormone (GH) response to growth hormone releasing hormone (GHRH) stimulation in hemodialysis patients.
Cremagnani L; Cantalamessa L; Orsatti A; Vigna L; Vallino F; Buccianti G
Clin Nephrol; 1993 May; 39(5):282-6. PubMed ID: 8513607
[TBL] [Abstract][Full Text] [Related]
11. Effect of recombinant human erythropoietin (rHuEpo) on the hemostatic system in chronic hemodialysis patients.
Huraib S; al-Momen AK; Gader AM; Mitwalli A; Sulimani F; Abu-Aisha H
Clin Nephrol; 1991 Nov; 36(5):252-7. PubMed ID: 1752076
[TBL] [Abstract][Full Text] [Related]
12. Autoreactive lymphocytotoxic IgM antibodies in highly sensitized dialysis patients waiting for a kidney transplant: identification and clinical relevance.
Barocci S; Valente U; Gusmano R; Perfumo F; Cantarella S; Leprini A; Icardi A; Nocera A
Clin Nephrol; 1991 Jul; 36(1):12-20. PubMed ID: 1889147
[TBL] [Abstract][Full Text] [Related]
13. Neutrophil and monocyte activation in chronic kidney disease patients under hemodialysis and its relationship with resistance to recombinant human erythropoietin and to the hemodialysis procedure.
Pereira R; Costa E; Gonçalves M; Miranda V; do Sameiro Faria M; Quintanilha A; Belo L; Lima M; Santos-Silva A
Hemodial Int; 2010 Jul; 14(3):295-301. PubMed ID: 20649681
[TBL] [Abstract][Full Text] [Related]
14. [Antibody response to histocompatibility antigens in hemodialysis patients subjected to planned whole-blood transfusions].
Fagiolo U; Corsano A; Antonello A; Venturi-Pasini C; Dal Lago O; Indiveri F
Minerva Chir; 1980 May; 35(10):701-4. PubMed ID: 7005724
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of anemia with recombinant human erythropoietin and the bone marrow response in uremic patients undergoing periodic hemodialysis].
García Martín F; Carrascosa Vallejo T; Martín Escobar E; Val Begueria J; Martín Hernández R; de Arriba G; Teno C; Salvatierra J
Rev Clin Esp; 1990 May; 186(9):419-22. PubMed ID: 2247677
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of anemia in patients with chronic renal insufficiency undergoing hemodialysis with recombinant human erythropoietin: 12 months' experience].
de Sousa FT; Prata MM; Barbas JV; dos Santos JP
Acta Med Port; 1990; 3(6):347-52. PubMed ID: 2089856
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of hypertension induced by erythropoietin in patients on hemodialysis.
Yamakado M; Umezu M; Nagano M; Tagawa H
Clin Invest Med; 1991 Dec; 14(6):623-9. PubMed ID: 1794212
[TBL] [Abstract][Full Text] [Related]
18. [Erythropoietin and transfusions in patients with anemia of chronic renal failure origin : an update view].
Duclos J; Olea C; Aguirre H; Alvarez MC; Salgado MC
Rev Med Chil; 1995 Apr; 123(4):451-5. PubMed ID: 8525189
[TBL] [Abstract][Full Text] [Related]
19. Long-term effects on quality of life in haemodialysis patients of correction of anaemia with erythropoietin.
Bárány P; Pettersson E; Konarski-Svensson JK
Nephrol Dial Transplant; 1993; 8(5):426-32. PubMed ID: 8393547
[TBL] [Abstract][Full Text] [Related]
20. [Human recombinant erythropoietin (rH-EPO) in chronic hemodialysis patients].
Jalil R; Vaccarezza A; Jara A; Lira P; Vial S; Serrano V
Rev Med Chil; 1990 Jun; 118(6):629-34. PubMed ID: 1775783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
